New drug combo targets Hard-to-Treat brain tumors
NCT ID NCT02142803
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 33 times
Summary
This early-phase study tests a new drug (MLN0128) combined with bevacizumab in 50 adults with recurrent glioblastoma or other advanced solid tumors. The goal is to find the safest dose and understand side effects. This is not a cure, but aims to control tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.